Dry Overactive Bladder

Summary

Introduction

Dry Overactive Bladder (dry OAB) is considered part of the overactive bladder syndrome. However, unlike wet overactive bladder (or urge urinary incontinence), it is normally only associated with urinary urgency and frequency, and not incontinence. Even so, recent studies suggest that these symptoms bother patients, with unpredictable urges disrupting daily activities and quality of life.

Scope

• Quantitative treatment data from 365 physicians based in US, Japan, France, Germany, Italy, Spain and UK; supported by key opinion leader comments
• Analysis of epidemiology, presentation and referral patterns, diagnostic assessment, and treatment strategy for dry OAB
• Influences on treatment choice and perception of current drug therapies including tolterodine, oxybutynin, darifenacin and solifenacin
• Evaluation of unmet needs and future outlook including awareness of R&D drug pipeline

Highlights

• Opinion leaders often recognize the impact that urge and frequency symptoms can have on a patient, even in the absence of incontinence episodes. However, prescribing physicians in general do not all accept this readily, leading to under prescribing in this patient group.
• For many years the terms urge urinary incontinence (UUI) and dry OAB have been used to describe separate syndromes with similar symptoms differentiated by the occurrence or not of incontinence. In fact is may be more suitable to consider overactive bladder as a continuum.
• Although pharmacological therapy is used less frequently in dry OAB than in UUI, the products chosen are similar, based on their activity on urge and frequency via detrusor activity; occasionally a less effective product with lower side effects may be chosen for dry OAB as opposed to a stronger, but less well tolerated product for UUI.

Reasons to Purchase

• Forecast product sales by understanding key aspects of dry OAB epidemiology, diagnosis and treatment
• Gain a better understanding of the challenges facing current and future players in the dry OAB market
• Identify physicians key concerns in dry OAB including unmet needs and the attributes that physicians believe are desirable for future treatments

Contents

• This product has been designed for delivery in a slide pack format (PowerPoint).
• Please select the slide pack option from the download menu at the side of the page
• Introduction
• Scope of this report
• Research and analysis highlights
• Key reasons to read this report
• Appendix A
  • Research methodology
  • Physician Sample breakdown
  • Urinary Incontinence and Overactive Bladder Insight Study - Physician Questionnaire
  • Section One Overview of Urinary Incontinence and overactive Bladder
  • Epidemiology
  • Presentation
  • Diagnosis
  • Referral pattern
  • Section Two Stress Urinary Incontinence
  • Diagnosis and treatment of SUI
  • Non-pharmacological treatment
  • Pharmacological treatment for SUI
  • Section Three Overactive Bladder With Urge Symptoms and/or Incontinence
  • Diagnosis and treatment of UUI
  • Pharmacological treatment for UUI
  • Diagnosis and treatment of 'dry OAB'
  • Pharmacological treatment for dry OAB
  • Section Four Mixed Stress/Urge Urinary Incontinence
  • Diagnosis and treatment of mixed SUI/UUI
  • Non-pharmacological treatment
  • Pharmacological treatment for mixed SUI/UUI
  • Section Five Interstitial Cystitis
  • Diagnosis and treatment of IC
  • Pharmacological treatment for IC
  • Section Six Drug Profiles
  • Section A: Drug influences on physicians' choice
  • Section B: The general treatment of urinary incontinence and overactive bladder
  • Contributing experts
  • US
  • Japan
  • Europe
• Appendix B
  • About Datamonitor
  • About Datamonitor Healthcare
  • About the CNS analysis team
  • Disclaimer